Antifungal Susceptibility of 3,4-di-hydropyrimidine-1-(H2)-L-H1-pyrrole Derivatives in Candida Clinical Isolates
There is an increasing rate of drug resistance to azole among Candida species, so, finding new compounds that are effective in laboratory conditions, such as 3,4-dihydropyrimidine derivatives are important. The purpose of this study was to evaluate the antifungal sensitivity of 3,4-di-hydropyrimidine-1- (H2) -L- H1-pyrrole derivatives in Candida isolates.
Antifungal sensitivity of 102 Candida isolates with the origin of otomycosis to dihydropyrimidine derivatives and itraconazole were evaluated by broth microdilution according to CLSI-M27S4 guidelines. The serial dilution range of compounds and antifungal drug was 0.016-16 μg/ml. A concentration of compounds that showed at least 50% growth inhibition compared to the positive control group was considered as the minimum inhibitory concentration (MIC). Statistical analysis was performed in SPSS V16.
Findings showed that 3,4-di-hydropyrimidine-1-(H2)-L-H1-pyrrole derivatives have higher MIC than itraconazole against Candida species. Also, comparing the MIC values of 3,4-di- hydropyrimidine with each other (P1-P4), P1 derivatives were found with lower MIC values than the other three derivatives and almost all compounds showed more efficacy against Candida albicans than other Candida species.
Although the antifungal effects of 3,4-dihydropyrimidine-1-(H2)-L-H1-pyrrole derivatives against Candida species were lower than itraconazole, but, making structural changes in these compounds can increase their antifungal effects.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.